Back to top
more

Galmed Pharmaceuticals Ltd. (GLMD)

(Delayed Data from NSDQ)

$5.37 USD

5.37
45,985

+0.05 (0.94%)

Updated Sep 20, 2019 03:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for GLMD

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Galmed Pharmaceuticals Ltd. [GLMD]

Reports for Purchase

Showing records 1 - 20 ( 129 total )

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 1

09/17/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GLMD

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 2

08/15/2019

Industry Report

Pages: 4

Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 3

08/06/2019

Company Report

Pages: 8

2Q19 Recap: Just Weeks Away From the Initiation of Phase 3 ARMOR Study in NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 4

08/06/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 5

08/05/2019

Company Report

Pages: 7

2Q19: ARMOR Enrolls By Hook or By Crook

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 6

07/08/2019

Industry Report

Pages: 3

Join Our Three-Part NASH Doc Series on "How Large is the NASH Opportunity?"

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 7

05/24/2019

Industry Report

Pages: 3

Healthcare -Recap of Our 27 Most Valuable Industry Notes in 2019

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 8

05/22/2019

Industry Report

Pages: 3

Healthcare -Recap of 34 Notes From Our Coverage of EASL 2019 and AASLD

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 9

05/08/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 10

05/08/2019

Company Report

Pages: 6

1Q19 - Don''t Underestimate ARMOR Phase 3 Trial - Timing

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 11

05/08/2019

Company Report

Pages: 8

ARMOR Set to Make Aramchol the Next Phase 3 NASH Contender; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 12

05/03/2019

Company Report

Pages: 8

Following EOP2 Meeting, ARMOR Design Protocol Is Set for a 3Q19 Pivotal Trial Start; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 13

04/16/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 14

04/15/2019

Daily Note

Pages: 4

GLMD at EASL: Stark Jetzt Than Ever

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 15

04/05/2019

Industry Report

Pages: 11

Healthcare - Walk Through Yas'' Shoes at EASL - Our EASL Roadmap

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 16

03/27/2019

Industry Report

Pages: 8

Healthcare - Part 2: Digging Through ICPT EASL Abstracts

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 17

03/15/2019

Industry Report

Pages: 8

NASH Weekly: Should You Go to EASL With Late Breakers Abstracts Revealed?

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 18

03/14/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 19

03/14/2019

Company Report

Pages: 6

4Q18 - Strengthening Its Armor

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 20

03/14/2019

Company Report

Pages: 8

BID Dosing Adds a Stronger Weapon to Aramchol''s ARMOR; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party